KROS   $56.64  -1.19% Market Open

Keros Therapeutics Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend pattern changed from нисходящий треугольник to симметричный треугольник.

2023-08-06 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-05 Trend pattern changed from канал to нисходящий треугольник.

2023-08-05 Signal in MACD changed from bullish to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: signal line crossed the middle level.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.


Current temperature: 12.32
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 9
Target Price Mean 91.33
Mean unverified/preliminary 91.33 / 91.33
Target Price Low / High 76.00 / 105.00
Median / STD DEV 88.00 / 10.57
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy Sell Sell
macd Sell None None
stoch Sell None None
ma20 Sell Sell None
ma50 Sell None None
ma100 Sell Sell None
Candlestick PatternSept. 13, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US4923271013
ceo Dr. Jasbir S. Seehra Ph.D.
Website https://www.kerostx.com
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.